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Background: Legionella pneumophila is an aerobic, pathogenic, gram-negative bacterium that infects hosts through contaminated cooling towers and other sources of water. Human infection presents as potentially life-threatening pneumonia, otherwise known as Legionnaires' disease. Purpose: Our study aimed to identify unrecognized outbreaks and geodemographic associations of Legionella in eastern Wisconsin. Methods: We retrospectively reviewed relevant geodemographic information of patients who underwent Legionella urine antigen testing (LUAT) at a single eastern Wisconsin health system from January 2013 to December 2017. A random sample inclusive of all positive tests was reviewed. If a patient was ever identified as positive, only the encounter in which they had their first positive test was included in the analyses. For all other patients, only their first negative test was included. Negative cases were used to investigate significant geodemographic differences in patients testing positive versus negative. Data was further explored using chi-squared, 2-sample t-tests and stepwise regression, followed by binary logistic regression for multivariable analysis. Geographic information for positive cases was mapped to locate hotspots. Results: Of all LUAT performed (n=21,599), 0.68% were positive. Among those in the random sample (n=11,652), positive LUAT cases were more prevalent in warmer months (June-November having 86.2% of all positive cases), younger, on average (59.4 years vs 67.7 years for negative cases), and disproportionately male (70.3% vs 29.7% negative); P<0.0001 for all. The prevalence of positive cases was higher among nonwhite race/ ethnicity (1.91% vs 1.01%; P<0.0001). Nonwhite race/ethnicity did not remain significant on multivariable analysis, suggesting age ± location may be an underlying predictor for infection. Overall, there were 13 zip codes in the city of Milwaukee containing 3 or more positive cases of Legionella. Within these zip codes, there were 58 positive cases. Of these, 36.2% were in zip codes of low socioeconomic status, 56.9% in zip codes of middle socioeconomic status, and the remaining 6.9% in zip codes of high socioeconomic status. Conclusion: The prevalence of a positive LUAT in eastern Wisconsin was less than 1%. Patients who are relatively younger, male, and nonwhite, and who are tested in warmer months, were more likely to test positive. This methodology, if done in real time, may complement public health detection of Legionnaires' disease outbreaks. Further study on built environments near clustered cases may reveal additional sources of infection.
Parvez Akhtar, Sam D. Zwernik, Amin B. Kassam, Richard A. Rovin
Aurora Research Institute; Aurora Neuroscience Innovation Institute
Background: An oncolytic virus must display tropism for the target cancer. This oncotropism is mediated by cell surface receptors that are differentially expressed by the cancer cell. Recent research into the mechanism of Zika virus (ZIKV)-induced microcephaly demonstrated that ZIKV has neurotropism for fetal neural progenitor cells, mediated by AXL, a member of the TAM (Tyro3, AXL, Mer) family of tyrosine kinase receptors. AXL is frequently overexpressed in majority of glioblastoma (GBM). We are attempting to repurpose ZIKV as an oncolytic virus that can specifically target and destroy glioblastoma through the AXL receptor. Purpose: We hypothesized that ZIKV could preferentially target and kill glioblastoma progenitor cancer cells through the AXL receptor. Methods: ZIKV strain MR766 was propagated in Vero cells. Viral stock was titrated by plaque assays. Western blot was used to characterize AXL expression in 5 commercial glioblastoma cell lines and 10 patient-derived glioblastoma progenitor cell lines. Cell lines were infected with ZIKV and the percentage of infected cells quantified by flow cytometry using the pan-flavivirus anti-E protein Ab 4G2. Cells were treated with AXL inhibitor (R428) and/or human AXL antibody, then ablated for AXL using CRISPR knockout prior to ZIKV exposure. Infected cells were quantified by flow cytometry. Immunofluorescence microscopy was performed to visualize ZIKV entry and replication. Glioblastoma progenitor cells were terminally differentiated into different types of brain cells and tested for ZIKV infection. Results: In this study, we found that AXL expression varies among our in-house patient-derived glioblastoma lines (7754, 7730,7714, 7753, 7978, 7759, 8034, 8035, 8049, and 7865) and commercial (ATCC) glioblastoma lines (LN229, A172, U251, and U87). Flow cytometry results confirmed that productive ZIKV infection only occurs in AXL-positive cells. We further found that ZIKV infection of our patient-derived glioblastoma cell lines was inhibited by AXL kinase inhibitor R428 in a dose-dependent manner. Furthermore, we found that blocking AXL receptor using AXL antibody significantly reduced ZIKV infection in glioblastoma in vitro. AXL knockout patient-derived glioblastoma lines (7759, 8034, 8035, 8049) completely blocked ZIKV infection and significantly inhibited viral replication. Our results highlight the dual role of AXL during ZIKV infection of glioblastoma: promoting viral entry and facilitating productive replication. We also found that ZIKV is unable to replicate in terminally differentiated glioblastoma progenitor cancer cells, suggesting selectivity for stem cells. Conclusion: These results clearly suggest that ZIKV displays oncotropism for glioblastoma progenitor cancer cells, mediated primarily through AXL receptor.
Purpose: This study aims to characterize justice-involved and non-justice-involved populations. Methods: Electronic health records from Aurora Health Care were used to identify a cohort of 564,988 patients, age 18-100 years by end of 2017, that lived in Milwaukee County for 360 or more days and had 2 or more in-person encounters between 2008 and 2017. Incarceration records were obtained from correctional facilities administered by Milwaukee County and the state of Wisconsin between May 2008 and June 2018. Unique persons were identified within these incarceration records (n=166,563) and cross-referenced to Aurora's electronic health record to determine which people had ever been patients (n=109,723). The cohort was separated into two groups: justice-involved (n=55,118) and not justice-involved (n=509,870), based on the presence of incarceration records for each cohort member. Next, clinical data from the electronic health record was incorporated into the cohort, and the two groups were compared using descriptive statistics. Results: In all, 43.5% were male, 66% white, and 24% African American, with the remaining belonging to Hispanic and other races. Mean age of the total population was 48.6 years (SD: 19.5). Odds ratios (OR) identified major independent predictors of justice involvement to be male gender (OR Patients who had a primary health care provider (OR: 0.7 [0.7-0.7]), were between 50 and 70 years old (OR: 0.5 [0.5-0.5]), or were older than age 70 (OR: 0.1 [0.1-0.1]) were less likely to have been recently justice-involved. Each odds ratio noted herein had a P-value of <0.01. Conclusion: Several demographic features associated with justice involvement in a health system population were identified. Future work aims to reduce potential confounders, such as patient neighborhood, and to delineate the impact of justice involvement on health metrics related to diseases known to be of higher prevalence in the justice-involved population.
Cardiac Catheterization and Risk Factors of Mortality
Reji Babygirija, Maharaj Singh, Richard A. Rovin, Kessarin Panichpisal
Aurora Research Institute; Aurora Neuroscience Innovation Institute
Background: Cardiac catheterization is the gold standard to diagnose and treat cardiovascular conditions, including pulmonary hypertension. Estimated annual rates for cardiac catheterization, for both sexes, range from 171 to 650 per 100,000 population (>20 years old). The risks and complications following cardiac catheterization are related to the patient's concomitant conditions as well as medications. There are limited data about the factors that influence the risk of serious adverse events after cardiac catheterization. Purpose: Identify the risk factors of mortality for patients undergoing cardiac catheterization procedure. Methods: This is a single-center retrospective data collection study on patients who underwent cardiac catheterization between January 2008 and March 2017. Demographics, comorbidities, and medications were included in Cox proportional hazards model. Results: A total of 11,062 patients were included in the study. Of these, 66% were male, 89.9% were white, 8.1% were black, and mean age of this cohort was 66. 
Conclusion:
This study revealed that the mean survival for cardiac catheterization patients was more than 6 years. Risk factors for mortality after cardiac catheterization were age, ethnicity, diabetes, myocardial infraction, coronary artery disease, hypertension, smoking, and prior history of stroke. However, medications, including aspirin, antiplatelets, ACE inhibitors, ARB, statin, nonstatins, and beta blockers, were found to be protective.
Evaluation of Beta Blockers and Renin-Angiotensin Inhibitors for the Reduction of Anthracycline-Induced Cardiotoxicity
Evan Mueller, Sarah Zukkoor Zorn, Rachel Pedersen, Vinay Thohan
Department of Pharmacy, Aurora Health Care; Tendick Center for Advanced Heart Failure Therapies
Background: Anthracyclines are known to cause dose-related cardiotoxicity. Clinical trials suggest that beta blockers and renin-angiotensin inhibitors may attenuate anthracycline-induced cardiotoxicity. However, studies are small with confounding factors, and guidelines remain inconsistent regarding optimal use of these medications for cardioprotection in oncology. Purpose: To evaluate the role of beta blockers and reninangiotensin inhibitors in reducing anthracycline-induced cardiotoxicity. Methods: A retrospective review was conducted for patients, age 18 years or older, who received anthracyclines at Aurora Health Care from January 2012 to December 2017. Patients on beta blockers or renin-angiotensin inhibitors prior to chemotherapy were compared to those not on these medications. The primary outcome was incidence of reduced left ventricular ejection fraction (LVEF), defined as time to first LVEF less than 53% by echocardiogram. Exclusion criteria included baseline LVEF of less than 53% and no baseline or postanthracycline echocardiogram. Continuous variables are expressed as means and standard deviations and compared between groups via Student's t-test. Categorical variables are shown as frequency and compared between groups via chi-squared test. Competing risks analysis was used to estimate rates of reduced LVEF, and proportional subdistribution hazards regression was used to identify a final multivariable model. Results: A total of 799 patients were included for analysis. Patients on beta blockers or renin-angiotensin inhibitors at anthracycline start were older, had higher body mass index, lower cumulative life dose, and lower alcohol use. Additionally, they had higher rates of atrial fibrillation/flutter, coronary artery disease, diabetes, heart failure, hyperlipidemia, and hypertension. A final multivariable model identified age of ≥65 years (hazard ratio [HR]: 2.11, 95% CI: 1.27-3.50; P<0.01), increasing cumulative life dose (HR per 50-unit increase: 1.13, 95% CI: 1.02-1.24; P<0.02), male sex (HR: 2.36, 95% CI: 1.42-3.93; P<0.01), and prechemotherapy LVEF of <60% (HR: 3.48, 95% CI: 2.13-5.69; P<0.01) as independent predictors of nonnormal LVEF. Conclusion: Within this cohort, patients on beta blockers or renin-angiotensin inhibitors at start of anthracycline therapy did not have a significant difference in incidence of postchemotherapy LVEF of <53% compared to patients not on those medications. Of note, the patients on medications had a higher incidence of preexisting cardiac disease, which may mask the potential cardioprotective benefits, confounding the results.
POSTER PRESENTATIONS

Real-Life Impact of Physician Awareness of a Positive Stool DNA Test on Subsequent Colonoscopy Outcome in Colorectal Cancer Screening
Julien Fahed, Aboud Affi
Department of Gastroenterology, Aurora Health Care
Background: A recent study of 244 subjects looked into clinical outcome of colonoscopy based on the physician's awareness of the positive stool DNA test result. The study compared unblinded unmonitored colonoscopy with blinded monitored colonoscopy. Purpose: We present a larger real-life study on the impact of physician awareness of a positive stool DNA test on colonoscopy results. Methods: Chart review of 1413 patients who had a positive stool DNA followed by documented subsequent colonoscopy was done. Attention was paid to the indication of the procedure in the colonoscopy report. A total of 5 patients were excluded; 3 of these had unknown indication and 2 a finding of "other carcinoma." Findings were recorded and patients were divided into two groups. Group 1 included patients who had indication of "stool DNA testing" or its equivalent, while group 2 included all the other indications. Only the index lesion was recorded. Advanced adenoma was defined as an adenoma larger than 10 mm or that had high-risk features such as villous transformation or high-grade dysplasia. Nonadvanced adenoma was defined as an adenoma smaller than 10 mm with no high-risk features. Statistical analysis with chi-squared was done to compare the proportions. A P-value less than 0.05 was considered statistically significant. Results: Of the 1408 patients, 979 (70%) had an indication of "stool DNA testing" or its equivalent, while 429 (30%) had another indication (to which we assumed the provider was not aware of the positive stool DNA testing). Results of group 1 and group 2 were as follows: Adenocarcinoma was found in 1.8% vs 1.4%, respectively (P=0.56); advanced adenoma was found in 24.8% vs 21.2%, respectively (P=0.14); >10-mm adenoma was found in 7.25% vs 6.99%, respectively (P=0.86); and nonadvanced adenoma was found in 28.7% vs 31.2%, respectively (P=0.57). Finally, no adenomas were found in 37.4% vs 39.2%, respectively (P=0.33).
Conclusion:
Following a positive stool DNA test, 1 out of 3 colonoscopies are done without the physician's awareness of the positive result. Fortunately, there was no difference in the outcome of colonoscopy whether the physician was aware of the positive result or not. Background: In October 2016, our health care facility adopted a new classification system for cesarean sections in an effort to have on-time cesarean deliveries among typically unscheduled patients with time-sensitive cesarean sections. Patients with timesensitive cesarean sections include those with an immediate threat to life (emergent) or those with maternal or fetal compromise that is not immediately life threatening (urgent). Even when a cesarean delivery is deemed emergent or urgent (ie, timesensitive), patient-, staff-, anesthesia-, and procedure-related delays may occur.
Calling Urgent and Emergent Cesarean
Purpose: Our quality improvement study aimed to assess whether caregiver education would improve on-time cesarean deliveries. Methods: We retrospectively studied all emergent (<15 minutes) and urgent (<30 minutes) cesarean sections within one labor and delivery unit. Patients 6 months prior to caregiver education were compared with those following nursing and provider education. Nursing and provider education (September 2017-October 2017) focused on development of communication pathways and reorientation to decision-making timelines. To compare groups, descriptive statistics and multivariable linear regression were used to predict time to incision. Results: A total of 149 patients pre-caregiver education and 185 patients post-caregiver education were included. Patients in the two groups did not differ by age, race/ethnicity, or body mass index (BMI). On univariate analysis, mean time from decision to incision, as well as mean time from decision to anesthesia in patients who did not already have anesthesia initiated, significantly improved (P<0.01). Additionally, delays significantly improved (67.1% vs 53.5%; P=0.01), although documented reasons for delays did not (P=0.14). Overall, only 21.1% of delayed patients (n=199) were emergent cesarean sections. Multivariable regression suggested case classification, patient delay, BMI, and time to anesthesia, but not the educational intervention, significantly predicted time to incision (P≤0.01; R 2 =0.86). Conclusion: Although an improvement in decision-toincision time was observed, it was unrelated to the educational intervention performed. Even so, concurrent nursing education initiatives aimed at improving cesarean section timing may have contributed to on-time emergent and urgent cesarean deliveries. Ultimately, ongoing education and team collaboration should continue in order to further improve cesarean delivery timing and patient care.
Criteria for Conversion From a Basal-Bolus Insulin Regimen in Patients With Type 2 Diabetes to a Regimen of a Glucagon-Like Peptide-1 Receptor Agonist With Basal Insulin
Christopher Klink, Kelsey Gardetto, Thomas Dilworth
Department of Pharmacy, Aurora Health Care
Background: Diabetes mellitus is a metabolic disease in which the body's production and response to insulin is altered. Type 2 diabetes mellitus is a subset of the disease in which the pancreas continues to produce insulin; however, the level of endogenous insulin production decreases over time. Many patients with type 2 diabetes mellitus eventually require basal-bolus insulin as part of their medication regimen; however, this regimen is complex and increases the risk of hypoglycemia and weight gain. A newer regimen for type 2 diabetes mellitus includes the combination of a glucagon-like peptide-1 receptor agonist (GLP-1RA) plus basal insulin. This regimen is less complex, safer, promotes weight loss, and has the potential to reduce cardiovascular risk. This regimen is incorporated in the American Diabetes Association guidelines as part of the step therapy for diabetes. What is less well known is which patients, if any, may be successfully de-escalated from basal-bolus insulin to this regimen. Purpose: To identify patient characteristics that predict a successful conversion from a basal-bolus insulin regimen to a basal insulin plus GLP-1RA regimen. Methods: A retrospective case series was performed on 32 patients with type 2 diabetes mellitus. Of the 32, 24 patients successfully made the conversion from a basal-bolus insulin regimen to GLP-1RA plus basal insulin; 8 patients were unsuccessful. Unsuccessful conversions were defined as discontinuation of the GLP-1RA due to intolerance, expense, or clinical decline seen in lab test values. Patient characteristics, including weight, hemoglobin A1c, and blood glucose (average and range), were tracked. C-peptide level, years since diagnosis, and insulin requirements also were analyzed to identify if there may be a correlation with patients who could successfully be converted. Results: Patients who successfully converted to a GLP-1RA plus basal insulin regimen had an average weight loss of 5.5 ± 2.0 kg and a reduction in average blood sugar of 16.3 ± 51.2 mg/dL at 3 months. They also had an average reduction in A1c of 0.83%; in comparison, patients who were unsuccessful had an average increase in A1c of 0.625%. The average C-peptide value for successfully converted patients was 2.77 ng/ml compared to 0.97 ng/ml for patients who failed the new regimen due to clinical decline. Conclusion: Patients with type 2 diabetes mellitus presently managed on basal-bolus insulin can be successfully converted to a GLP-1RA plus basal insulin if appropriately screened and selected.
Vagal Response During Pulmonary Vein Isolation With Cryoballoon Ablation
Janet C. Tsang, Lynn Erickson, Imran Niazi, Jasbir S. Sra, M. Eyman Mortada
Aurora Cardiovascular Services; Aurora Research Institute
Background: Vagal nerve response, seen during cryoballoon ablation of the pulmonary veins, can be attributed to the ablation's effect on the ganglionated plexi. This effect is demonstrated with drops in blood pressure and heart rate during pulmonary vein isolation with cryoballoon ablation. Purpose: To evaluate surrogate markers for vagal response during pulmonary vein isolation with cryoballoon ablation. Methods: A total of 22 patients with paroxysmal atrial fibrillation underwent pulmonary vein isolation with a 28-mm second-generation cryoballoon using a 3-minute freeze technique. Two or more lesions were performed for each vein. Initial blood pressure, nadir blood pressure, time to reach -30 degrees, time to reach -40 degrees, time from start of thaw to reach zero degrees (TT0), time from start of thaw to the nadir blood pressure (TTNBP), total freeze time, minimal temperature reached, and time from start of freeze to vein isolation by electrogram were recorded. Clustered data for each vein were analyzed using the common slope and linear intercept mixed model. Results: All patients (mean age: 62.5 ± 8.4 years; male sex: 69%, body mass index: 31.7 ± 5.7; mean CHA 2 DS 2 -VASc score: 1.8 ± 1.2; white race: 100%; hypertension: 56%; coronary artery disease: 38%; sleep apnea: 50%; mean left atrial volume index: 58.6 ± 17.8 ml/m 2 ; left ventricular ejection fraction of ≥55: 100%) had paroxysmal atrial fibrillation. Univariate analysis demonstrated that the best surrogate marker for vagal response was the TT0 in the inferior veins. The drop in blood pressure increased up to fourfold, with a onefold increase in thawing duration (TT0 in left inferior vein: 3.040, P<0.020; TT0 in right inferior vein: 4.261, P<0.046). Average TT0 and drop of systolic blood pressure were 7.5 seconds and 21 mmHg, respectively, in the left inferior vein, and 7 seconds and 20.8 mmHg, respectively, in the right inferior vein. The second marker was the TTNBP, seen only in the right superior vein, with average time of 86.6 seconds, causing an average of systolic blood pressure drop of 24.6 mmHg. A threefold increase in TTNBP caused onefold increase in blood pressure drop (0.323, P<0.037). Conclusion: Vagal response during cryoballoon ablation was seen mainly during isolation of the inferior pulmonary veins.
Evaluation of Opioid Prescribing Habits and Morphine Milligram Equivalent Trends at Aurora Health Care
Brent Davis, Prati Wojtal, Joel Pietryga, Barry McClain, Tristan F. Edwards
Department of Pharmacy, Aurora Health Care
Background: Aurora Health Care's opioid stewardship committee (OSC) was created to optimize and standardize pain management in patients while minimizing the use of opioids and reducing the number of patients who develop opioid use disorder. In 2016, the Centers for Disease Control and Prevention (CDC) established guidelines for prescribing opioids, but execution and awareness of the current guidelines is inconsistent across the system. An initiative of the OSC is to ensure that all providers are following the CDC opioid-prescribing guidelines. The specific goals of this committee are to: 1) reduce the total amount of opioids prescribed in morphine milligram equivalents (MMEs); 2) reduce the number of patients co-prescribed opioids and benzodiazepines; and 3) minimize the number of patients started on chronic opioid agonist therapy. Purpose: An opioid-prescribing dashboard was designed to assess baseline opioid-prescribing practices and the goals of the OSC. The opioid-prescribing dashboard provides leadership visibility to MME prescribing trends and prescribing practices deviating outside the CDC opioid-prescribing guidelines. Methods: OSC members identified important definitions and metrics for reporting in the dashboard. Metrics were adopted from literature reviews of successful opioid dashboards at other health systems and in harmony with CDC opioid-prescribing guidelines. MME reports are the key catalyst to the dashboard's analysis. In 2018, Aurora linked daily MME calculations to opioid prescriptions in its electronic health record (EHR). In October 2018, CDC MME conversion factors were used to validate EHR's daily MME calculations for opioids prescribed. Incorrect or missing MME calculations were identified and addressed. An initial report was developed allowing for baseline reporting during November 1, 2018-January 31, 2019. The data was filtered by provider, specialty, and service area and then manipulated for reporting on the dashboard. Results: During the 3-month period, 105,874 opioid prescriptions, with an average daily MME of 40, were prescribed. The average monthly MME total was 21.8 million, with 29% and 15% of patients tallying a daily MME of ≥50 and ≥90 on opioids. Aurora averaged 1229 new chronic opioid patients each month and currently accounts for 8307 total chronic opioid patients. In January 2019, 68% of patients prescribed opioids were prescribed benzodiazepines between September 1, 2018, and January 31, 2019. Conclusion: The dashboard identifies trends and areas for improvement in prescribing opioids with the intention to encourage safe and appropriate prescribing for Aurora patients.
Strengthening the Culture of Well-Being in Graduate Medical Education
Jacob Bidwell, Tricia La Fratta, Deborah Simpson, Nicole Eull
Departments of Family Medicine, Graduate Medical Education, and Academic Affairs, Aurora Health Care
Background: Physician burnout is a safety, quality, and workforce issue. As a result, well-being is an Accreditation Council on Graduate Medical Education's (ACGME) accreditation requirement for the sponsoring institution and individual programs. Aurora Health Care's graduate medical education (GME) leaders convened a retreat of key stakeholders (program directors, resident council leaders, system leaders) to develop a well-being strategic plan. Each program completed the ACGME's Inventory of Elements of Your Program's Well-Being plan, and GME leaders completed Inventory of Elements of Your Institution's Well-Being plan. At the retreat cross-cutting findings were identified, with action items identified. Purpose: To improve our resident/fellow well-being scores through the development of clear GME protocols, procedures, and initiatives with pre/post metrics. Methods: Major GME strategic action items focused on aligning physician contracts with teaching roles, procuring funds for a medical education well-being position, developing direct access for trainees to behavioral health, developing a systemwide budget for ensuring a standard for adequate time and space for pursuing wellbeing, and developing a crisis communication protocol. The impact of our interventions was measured by the evidence-based Mayo Well-Being Index (MWBI) and the ACGME's well-being survey. Results: All action items have been implemented, including appointment of a 0.80 FTE well-being director. Our resident/fellow wellness scores were positive. MWBI results showed a 4.6% decrease (17.3% to 12.7%) of residents/fellows (n=158) reporting high levels of distress over the last 11 months, well below the national average of 34.9% (>1700 residents/fellows). Our ACGME well-being survey results were within normal range per national metrics.
program for incoming interns to jump-start a "connection" with their continuity clinic team shortly after match day. This early and sustained contact provides interns with an immediate resource for questions/support and ongoing connections with senior residents and a faculty advisor. 2) Fit4Life intervention continued to build/ support colleague relationships through personal fitness. Wellness challenges between trainee years were held to promote physical health per American Heart Association (AHA) exercise guidelines. Three measures -a Fit4Life survey, semi-structured interviews with interns, and Mayo Well-Being Index (MWBI) -were used to evaluate process and outcomes. Results: Fit4Life pre-, during, and postchallenge data showed that less than 20% of internal medicine residents met AHA guidelines: 150 minutes/week of aerobic physical activity. Challenge period results showed a modest but not significant increase in exercise. Average completion rate was 83% of internal medicine residents. Exercise, per AHA recommendations, was paired >50% of time with another activity (eg, watch/listen to television, movies, music, podcasts; connecting with family/friends). RAP intern interviews (13 of 13 [100%]) revealed that 85% were supportive of RAPS and 100% met weekly with RAPS team member(s) at continuity clinic. MWBI scores throughout intervention were well below instruments established at risk level for burnout (5.0), with below burnout scores ranging from 3.1 preintervention (February 2018) to 2.3 postintervention (December 2018).
Conclusion:
The results of our well-being interventions focused on supportive colleague relationships through RAPS and exercise reveal high participation rates and support but no significant impact on physical or mental health as measured by Fit4Life and MWBI.
Health Care Utilization as a Proxy to Introduce a Novel Disease Screen in Pediatric Populations
Angela A. Navarrete-Opazo, Maharaj Singh, Mindy R. Waite, Sheldon R. Garrison
Aurora Research Institute
Background: The global economic burden of treating genetically distinct conditions is growing rapidly. An interest in prophylactic treatment and pharmacogenetic decision-making has emerged in concert with an increasing usage of genetic tools, such as prenatal genetic testing, biomarker assays, and personal genomic tests, to presymptomatically identify these conditions. However, little is known about the optimal timing of these approaches to best impact patient care and, where applicable, to consider the cost of care in providing prophylactic treatment. Purpose: To determine the optimal developmental timepoint in early childhood to screen for certain health conditions presymptomatically and measure the financial impact of the resulting clinical actions. Methods: A retrospective review of vaccination compliance, as a proxy for health care utilization, of the 3,969,953 eligible individuals from 2012 through 2018 using de-identified data from the Wisconsin Immunization Registry. Further analysis across racial groups was assessed, and the financial impact of changes in cost of care. Concurrently, a parental survey was conducted to determine preference for the timing and disease inclusions of genetic tests. Results: Overall vaccination rates revealed maximal compliance during the first 6 months of visits, with the highest compliance rate at month 4 (71.2%). However, this rate significantly differed when racial groups were assessed independently, with compliance in Caucasian children highest at 4 months (80.0%) and all other racial backgrounds highest at 2 months (66.3%-72.6%). Conclusion: Results demonstrated that health care utilization is greatest within the first 4 months after birth, suggesting an optimal time to administer tests designed to detect health conditions presymptomatically.
Incidence of Atypia or Malignancy on Surgical Excisional Biopsy From Benign Papillomas Diagnosed on Core Biopsy
Salik Nazeer, Mark T. Lawton, Joseph J. Weber, Franklin R. Zuehl
Departments of Radiology, Surgery, and Pathology, Aurora Health Care
Background: Solitary intraductal papillomas are benign, proliferative, mass-forming lesions arising in the lactiferous ductal system of the breast. Solitary intraductal papillomas are encountered with core biopsy of the breast, with an incidence of approximately 5%. Although papillomas are considered benign, the lesions frequently are surgically excised after diagnosis on core biopsy. Excision has historically been performed due to a certain percentage of core biopsy cases being reclassified (upstaged) to atypia or malignancy based on pathologic results of excisional biopsy. Purpose: The objective of this study is to determine the incidence of solitary intraductal papillomas that were subsequently reclassified to atypia or malignancy following complete surgical excision. Methods: A retrospective analysis was performed that included review of pathology results and other data for intraductal papillomas diagnosed by core biopsy from 2010 through 2016 at participating Milwaukee-metropolitan Aurora Health Care facilities. Female patients with documented personal history of breast carcinoma prior to the core biopsy procedure and patients under the age of 18 were excluded from the study. Reports were reviewed by 4 different investigators to identify subsequent excisional biopsy results as well as follow-up radiology to confirm diagnoses. All data were reported using descriptive statistics. Results: Our initial review included 390 patients who had the diagnosis of papilloma from a core biopsy. Of those, 154 patients did not undergo excisional biopsy (39%). Of the 236 patients who had excisional biopsies, 203 patients had benign specimens (86%), 15 had atypia with intraductal papilloma (6%), 11 had adjacent atypia (5%), and 7 had malignancy (3%). The 7 patients with malignancy were reevaluated radiographically to assess for concordance of the core biopsy and excisional biopsy results. Of the 7, 3 patients with core biopsy-proven papilloma demonstrated malignancy within the existing lesion (1%) on subsequent excisional biopsy, and 4 patients were excluded due to lack of concordance between radiology and pathology findings comparing core biopsy location to excisional biopsy position. Conclusion: In our facilities, only 1% of patients with initially diagnosed benign breast papillomas at core biopsy demonstrated true associated malignancy on the excisional biopsy specimen, a significantly lower rate than reported incidences in most similar previous studies. Our study is limited by our sample size. Further prospective studies would be helpful to further validate this data.
Methods: During 2018, new at-risk patients were identified and tracked at two family medicine sites. Each patient verbally consented to voluntary participation in the hot spotting intervention. A new interdisciplinary team was created at the second clinic site, which required additional buy-in to the intervention's concepts. We compared number of hospital admissions, emergency department (ED) visits, and estimated cost savings before and after a 9-month intervention period. Basic descriptive statistics were conducted to describe the overall population. Paired t-tests were used as appropriate. A P-value less than 0.05 was associated with statistical significance. Results: A total of 35 new "hot spot" patients were identified. This patient cohort had mean age of 56 years and was predominately female (69%). Prevalence of mental illness was 89%. Additionally, 66% had communication problems (17% with primary language other than English), 63% had caregivers suffering from caregiver fatigue, and 49% had safety concerns. Furthermore, 34% of patients were considered underutilizers of health care. Although not statistically significant, mean total ED visits (3.6 vs 2.7; P=0.102) and hospital admissions (1.3 vs 0.8; P=0.087) decreased per person. Charlson scores did not change following the intervention. Cost reduction based on these decreased rates was determined at $87,000 ($2485/ patient), equating to a 2.09 return on investment. Even without knowing the financial aspects, clinic staff were very satisfied with the intervention. Overall, 97% of provider respondents felt hot spotting patients was a good idea after the intervention, compared to 78% before, and 76% felt the intervention helped them take better care of their patients. Conclusion: Extending our hot spotting intervention to an additional clinic site showed similar decreases in hospital and ED utilization as previously reported. Moreover, there continued to be cost savings at both sites. Therefore, our pilot efforts will be extended to a third nonresidency clinic site in 2019 for further evaluation.
Reduced Esophageal Cooling With Left Atrial Roof and Posterior Wall Cryoablation
Dhruv Chawla, Lynn Erickson, Mohamed Djelmami-Hani, Imran Niazi
Aurora Cardiovascular Services; Aurora Research Institute
Background: Thermal esophageal injury is a rare but devastating complication of pulmonary vein isolation using radiofrequency energy or cryoablation (CRYO) and also radiofrequency ablation of posterior wall (PW). Risk of esophageal injury with PW and roof CRYO is unknown. Since PW and roof CRYO has recently been advocated, we studied minimum esophageal temperature (MET) to assess safety of PW and roof CRYO. Purpose: To assess safety of PW and roof CRYO for atrial fibrillation. Methods: CRYO was performed in 16 patients (mean age: 64 ± 9 years; mean left atrial volume: 59 ± 24 mL/m 2 ; male sex: 12) with atrial fibrillation (8 paroxysmal, 8 persistent). Following pulmonary vein isolation, CRYO balloon was dragged across the roof and PW with lesions delivered at half-balloon-width intervals. CRYO balloon and esophagus were precisely localized to 1 mm accuracy with Navik 3D mapping system (APN Health, LLC, Waukesha, WI). Lesions were maintained for 3 minutes unless a MET of <28°C was encountered. Incidence of lesions
